AZ-Glenmark Saxagliptin Case Heads For Settlement?

More than a year after AstraZeneca PLC. hauled Glenmark to court over intellectual property rights issues concerning its dipeptidyl peptidase-4 (DPP-4) inhibitor for diabetes, Onglyza (saxagliptin), in India, there are some signs of a potential thaw in the legal tussle.

A settlement has been broached in the case, with the matter being referred to the Delhi High Court Mediation and Conciliation Centre.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Gilead Ready To Go After Hepatitis D Again

26 May 2025

• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.